Get the Stockscreener App
2.18
5.63%
-0.13
After Hours:
2.24
0.06
+2.75%
Ventyx Biosciences Inc stock is traded at $2.18, with a volume of 1.14M.
It is down -5.63% in the last 24 hours and down -2.24% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$2.31
Open:
$2.31
24h Volume:
1.14M
Relative Volume:
0.90
Market Cap:
$157.59M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-0.7786
EPS:
-2.8
Net Cash Flow:
$-167.04M
1W Performance:
-11.38%
1M Performance:
-2.24%
6M Performance:
-60.36%
1Y Performance:
-93.72%
1-Day Range:
$2.155
$2.338
1-Week Range:
$2.155
$2.66
52-Week Range:
$1.79
$34.49
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(858) 945-2393
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Gaining Ground: Ventyx Biosciences Inc (VTYX) Closes Lower at 2.31, Down -2.12 - The Dwinnex
Take off with Ventyx Biosciences Inc (VTYX): Get ready for trading - SETE News
VTYX Stock Rises on Strategic Equity Investment Deal With SNY - MSN
Deerfield Management Company L.P. Series C Buys 2,287,570 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat
Stock Surge: Ventyx Biosciences Inc (VTYX) Closes at 2.39, Marking a -2.85 Increase/Decrease - The Dwinnex
Ventyx Biosciences, Inc. (NASDAQ:VTYX) to Post FY2024 Earnings of ($2.13) Per Share, HC Wainwright Forecasts - MarketBeat
Sanofi’s $27 Million Investment in Ventyx Biosciences - Global Legal Chronicle
Adversity is less terrifying than hope: Ventyx Biosciences Inc (VTYX) - SETE News
Ventyx Biosciences retains stock target, neutral rating despite Sanofi's $27M stake - Investing.com
VTYX Stock Rises on Strategic Equity Investment Deal With SNY - Yahoo Finance
Benjamin F. Edwards & Company Inc. Buys 16,858 Shares of Twist Bioscience Co. (NASDAQ:TWST) - MarketBeat
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Pharmaceutical Technology
Ventyx Biosciences Inc (VTYX) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Ventyx Biosciences (NASDAQ:VTYX) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Yahoo Finance
Ventyx stock climbs 8% on $27M Sanofi investment - MSN
Thoughtworks (NASDAQ:TWKS) Sees Large Volume Increase - Defense World
VTYX’s Q2 earnings predictions: What the experts say - US Post News
Sanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright - TipRanks
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M - Fierce Biotech
Victory Capital (NASDAQ:VCTR) Hits New 12-Month High at $56.29 - MarketBeat
Ventyx stock climbs 8% on $27M Sanofi investment (NASDAQ:VTYX) - Seeking Alpha
Sanofi invests $27 million in Ventyx Biosciences By Investing.com - Investing.com India
Sanofi invests $27 million in Ventyx Biosciences By Investing.com - Investing.com Canada
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment - Marketscreener.com
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment - Morningstar
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment - MarketWatch
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi - GlobeNewswire
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi - Marketscreener.com
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi - Yahoo Finance
(TWST) Pivots Trading Plans and Risk Controls - Stock Traders Daily
How the (TVE) price action is used to our Advantage - Stock Traders Daily
Seven Eight Capital LP Buys Shares of 22,269 Victory Capital Holdings, Inc. (NASDAQ:VCTR) - MarketBeat
Ventyx Biosciences Repeat Insider Selling Not A Positive Indicator - Simply Wall St
JT Extends Vector Tender - Tobacco Reporter
Taking a Closer Look At Ventyx Biosciences Inc (VTYX) Following Its Recent Trade - Knox Daily
Ventyx Biosciences Inc (VTYX) looking to reclaim success with recent performance - SETE News
Acadian Asset Management LLC Makes New Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat
VTYX overperforms with a 2.18 increase in share price - US Post News
Market Momentum Report: Ventyx Biosciences Inc (VTYX)’s Positive Close at 2.29 - The Dwinnex
VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ventyx Biosciences, Inc. - AccessWire
Ventyx Biosciences Inc (VTYX)’s stock price range in the last year - US Post News
Ventyx Biosciences Inc (VTYX) Stock: A Year of Decreases and Increases - The InvestChronicle
Ventyx Edges Forward on Parkinson's Test Results - MSN
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives $8.29 Consensus Price Target from Analysts - MarketBeat
Ventyx Edges Forward on Parkinson’s Test Results - Baystreet.ca
Ventyx Biosciences Announces Initiation of Dosing in a - GlobeNewswire
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease - Yahoo Finance
Ventyx Biosciences Inc (VTYX) is looking forward to a strong quarter - SETE News
Analyzing Ratios: Ventyx Biosciences Inc (VTYX)’s Financial Story Unveiled - The Dwinnex
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):